ホーム › 肺がん › サウスダコタ › Sioux Falls
Sioux Falls、SDにおける肺がんの臨床試験
Sioux Fallsとその周辺地域（約30マイル以内）の拠点で、肺がんに関する14件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
被験者募集中第3相
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
被験者募集中第3相
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
被験者募集中第3相
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
被験者募集中第3相
- Avera Cancer Institute, Sioux Falls
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
被験者募集中第3相
- Sanford Cancer Center ( Site 0053), Sioux Falls
- Avera Cancer Institute- Research ( Site 0090), Sioux Falls
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
被験者募集中第2相
- Sanford Cancer Center ( Site 0038), Sioux Falls
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
被験者募集中第3相
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
被験者募集中第2相
- Sanford Cancer Center, Sioux Falls
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
被験者募集中第2相
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2/3相
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2相
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Avera Cancer Sequencing and Analytics Protocol (ASAP)
被験者募集中観察研究
- Avera Cancer Institute, Sioux Falls
他の都市における肺がんの試験
- Houston, TX78件の研究
- Boston, MA62件の研究
- New York City, NY60件の研究
- Los Angeles, CA45件の研究
- Arlington, VA41件の研究
- Washington, DC41件の研究
- Chicago, IL41件の研究
- Baltimore, MD40件の研究
- Nashville, TN40件の研究
- St. Louis, MO39件の研究
- Columbus, OH37件の研究
- Philadelphia, PA36件の研究
Sioux Fallsにおける他の研究
- 非小細胞肺癌19件の研究
- 乳がん18件の研究
- 卵巣がん16件の研究
- がん（全種類）13件の研究
- 子宮内膜がん11件の研究
- 転移性癌10件の研究
- 大腸癌9件の研究
- 頭頸部扁平上皮癌9件の研究
- 心不全7件の研究
- 結腸癌7件の研究
- トリプルネガティブ乳がん7件の研究
- 前立腺がん7件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。